MD1920F2 - Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer - Google Patents

Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer

Info

Publication number
MD1920F2
MD1920F2 MD99-0262A MD990262A MD1920F2 MD 1920 F2 MD1920 F2 MD 1920F2 MD 990262 A MD990262 A MD 990262A MD 1920 F2 MD1920 F2 MD 1920F2
Authority
MD
Moldova
Prior art keywords
composititon
alzheimer
prevention
delay
disease origin
Prior art date
Application number
MD99-0262A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD990262A (en
Inventor
Егон НОВАК
Original Assignee
Форбес-Тек Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Форбес-Тек Инк. filed Critical Форбес-Тек Инк.
Publication of MD990262A publication Critical patent/MD990262A/xx
Publication of MD1920F2 publication Critical patent/MD1920F2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MD99-0262A 1997-12-18 1998-12-18 Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer MD1920F2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (2)

Publication Number Publication Date
MD990262A MD990262A (en) 2000-06-30
MD1920F2 true MD1920F2 (ro) 2002-05-31

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
MD99-0262A MD1920F2 (ro) 1997-12-18 1998-12-18 Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer

Country Status (18)

Country Link
US (1) US5985936A (hu)
EP (1) EP0967982A2 (hu)
CN (1) CN1252724A (hu)
AU (1) AU1656099A (hu)
BG (1) BG103740A (hu)
BR (1) BR9807577A (hu)
CA (1) CA2281710A1 (hu)
EE (1) EE9900354A (hu)
GE (1) GEP20022783B (hu)
HU (1) HUP0100737A3 (hu)
LT (1) LT4801B (hu)
LV (1) LV12438B (hu)
MD (1) MD1920F2 (hu)
NO (1) NO993979L (hu)
PL (1) PL335421A1 (hu)
RU (1) RU2173151C2 (hu)
SK (1) SK112999A3 (hu)
WO (1) WO1999032097A2 (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
IL152175A (en) 2000-04-14 2005-08-31 Mars Inc Compositions and methods for improving vascular health
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20050277129A1 (en) * 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
US7704955B2 (en) * 2004-11-24 2010-04-27 Neopro Pain, Inc. Methods and compositions for modulating conditions in both mammals and plants
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123617A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for reducing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
MX2020002884A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
US20230263809A1 (en) 2019-12-24 2023-08-24 Folium Biosciences Europe B.V. Food supplement for alzheimer
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010033A1 (en) * 1994-09-29 1996-04-04 The University Of British Columbia Sterol compositions from pulping soap

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
CA2289531C (en) * 1997-05-15 2009-09-29 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010033A1 (en) * 1994-09-29 1996-04-04 The University Of British Columbia Sterol compositions from pulping soap
MD1721C2 (ro) * 1994-09-29 2002-01-31 The University Of British Columbia Procedeu de separare a compoziţiei de fitosteroli din săpun de pulpă, compoziţie de reducere a nivelului de colesterol şi produs terapeutic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEISGRABER et al. Lipoproteins, neurobiology, and Alzheimer(s disease: Structure and function of apolipoprotein-E. Curr. Opin. Struct. Biol. 1994, 4, p. 507-515 *

Also Published As

Publication number Publication date
CA2281710A1 (en) 1999-07-01
HUP0100737A3 (en) 2002-07-29
NO993979D0 (no) 1999-08-18
BR9807577A (pt) 2001-08-07
WO1999032097A2 (en) 1999-07-01
BG103740A (en) 2000-05-31
WO1999032097A3 (en) 1999-09-02
LT99114A (lt) 2001-01-25
NO993979L (no) 1999-10-13
EP0967982A2 (en) 2000-01-05
EE9900354A (et) 2000-02-15
RU2173151C2 (ru) 2001-09-10
LT4801B (lt) 2001-06-25
AU1656099A (en) 1999-07-12
GEP20022783B (en) 2002-09-25
US5985936A (en) 1999-11-16
CN1252724A (zh) 2000-05-10
LV12438A (en) 2000-03-20
PL335421A1 (en) 2000-04-25
HUP0100737A2 (hu) 2001-09-28
LV12438B (en) 2000-09-20
SK112999A3 (en) 2001-11-06
MD990262A (en) 2000-06-30

Similar Documents

Publication Publication Date Title
MD1920F2 (ro) Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer
RU99120072A (ru) Способ и композиция для профилактики и задержки начала болезни Альцгеймера
EP0402950A3 (en) Treatment of postmenopausal disorders
CA2223397A1 (en) Novel nor-pregnanes for inducing hypothalamic effects
MY104535A (en) Oral composition for the treatment of inflammatory bowel diseases.
HU9503578D0 (en) Androstane steroids as neurochemical initilators of change in human hypothalamic function and related pharmaceutical compositions and methods
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
EP0914165A4 (en) STEROIDS USED AS NEUROCHEMICAL STIMULATORS OF THE VOMERO-NASAL ORGANS AND RELIEVING PREMENSTRUAL AND ANXIETY SYMPTOMS
HU9503579D0 (en) Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
EP0924219A3 (en) Novel estrenes for inducing hypothalamic effects
ZA965891B (en) Tnf receptor and steroid hormone in a combined therapy
MX9700881A (es) Pregnanos y colanos como indicadores neuroquimicos del cambio en la funcion hipotalamica.
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
MXPA94000705A (es) Esteroides de estreno como iniciadores neuroquimicos del cambio en la funcion hipotalamica humana ycomposiciones farmaceuticas y metodos relacionados.
BR9816142A (pt) Esteróides de 19-nor-colano como iniciadores neuroquìmicos de mudança na função hipotalâmica humana
IL137496A0 (en) Dosage form and pharmaceutical kit for increasing the oral availablity of pharmaceutical agents